Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin

Laboratory investigation

View More View Less
  • 1 Department of Neurosurgery, Oncology and Biomedical Engineering, School of Medicine;
  • 2 Department of Neurology, Kennedy Krieger Institute, Johns Hopkins University, Baltimore, Maryland;
  • 3 Vascular Biology Program, Department of Surgery, Children's Hospital Boston and Harvard Medical School; and
  • 4 Center of Cancer Systems Biology, St. Elizabeth's Medical Center, Tufts Medical School, Boston, Massachusetts
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

Brain tumors pose many unique challenges to treatment. The authors hypothesized that Fc-endostatin may be beneficial. It is a newly synthesized recombinant human endostatin conjugated to the Fc domain of IgG with a long half-life (weeks) and unknown toxicity. The authors examined the efficacy of Fc-endostatin using various delivery methods.

Methods

Efficacy was assessed using the intracranial 9L gliosarcoma rat model treated with Fc-endostatin for use in rodents (mFc-endostatin), which was administered either systemically or locally via different delivery methods. Oral temozolomide (TMZ) was administered in combination with mFc-endostatin to determine if there was a beneficial synergistic effect.

Results

Intracranial delivery of mFc-endostatin via a polymer or convection-enhanced delivery 5 days after tumor implantation increased median survival, compared with the control group (p = 0.0048 and 0.003, respectively). Animals treated weekly with subcutaneous mFc-endostatin (started 5 days post–tumor implantation) also had statistically improved survival as compared with controls (p = 0.0008). However, there was no statistical difference in survival between the local and systemic delivery groups. Control animals had a median survival of 13 days. Animals treated either with subcutaneous mFc-endostatin weekly or with polymer had a median survival of 18 and 15 days, respectively, and those treated with oral TMZ for 5 days (Days 5–9) had a median survival of 21 days. Survival was further increased with a combination of oral TMZ and mFc-endostatin polymer, with a median survival of 28 days (p = 0.029, compared with TMZ alone). Subcutaneous mFc-endostatin administered every week starting 18 days before tumor implantation significantly increased median survival when compared with controls (p = 0.0007), with 12.5% of the animals ultimately becoming long-term survivors (that is, survival longer than 120 days). The addition of TMZ to either weekly or daily subcutaneous mFc-endostatin and its administration 18 days before tumor implantation significantly increased survival (p = 0.017 and 0.0001, respectively, compared with TMZ alone). Note that 12.5% of the animals treated with weekly subcutaneous mFc-endostatin and TMZ were long-term survivors.

Conclusions

Systemically or directly (local) delivered mFc-endostatin prolonged the survival of rats implanted with intracranial 9L gliosarcoma. This benefit was further enhanced when mFc-endostatin was combined with the oral chemotherapeutic agent TMZ.

Abbreviations used in this paper: CED = convection-enhanced delivery; FITC = fluorescein isothiocyanate; hFc- and mFc-endostatin = Fc-endostatin for use in humans and in rodents, respectively; p(CPP:SA) = polyanhydride poly(1,3-bis-[p-carboxyphenoxy] propane-co-sebacic anhydride) polymer; TMZ = temozolomide.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address correspondence to: Betty Tyler, Department of Neurosurgery, Johns Hopkins Medical Institution, 1550 Orleans Street/CRB2 Room 2M45, Baltimore, Maryland 21231. email: btyler@jhmi.edu.

Please include this information when citing this paper: published online September 16, 2011; DOI: 10.3171/2011.8.JNS11125.

  • 1

    Bergers G, , Javaherian K, , Lo KM, , Folkman J, & Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808812, 1999

    • Search Google Scholar
    • Export Citation
  • 2

    Brem S, , Tyler B, , Li K, , Pradilla G, , Legnani F, & Caplan J, : Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60:643650, 2007

    • Search Google Scholar
    • Export Citation
  • 3

    Celik I, , Sürücü O, , Dietz C, , Heymach JV, , Force J, & Höschele I, : Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:1104411050, 2005

    • Search Google Scholar
    • Export Citation
  • 4

    Degen JW, , Walbridge S, , Vortmeyer AO, , Oldfield EH, & Lonser RR: Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 99:893898, 2003

    • Search Google Scholar
    • Export Citation
  • 5

    Dhanabal M, , Ramchandran R, , Volk R, , Stillman IE, , Lombardo M, & Iruela-Arispe ML, : Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59:189197, 1999

    • Search Google Scholar
    • Export Citation
  • 6

    Ding YH, , Javaherian K, , Lo KM, , Chopra R, , Boehm T, & Lanciotti J, : Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci U S A 95:1044310448, 1998

    • Search Google Scholar
    • Export Citation
  • 7

    Eder JP Jr, , Supko JG, , Clark JW, , Puchalski TA, , Garcia-Carbonero R, & Ryan DP, : Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:37723784, 2002

    • Search Google Scholar
    • Export Citation
  • 8

    Folkman J: Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 312:594607, 2006

  • 9

    Gaspar LE, , Fisher BJ, , Macdonald DR, , LeBer DV, , Halperin EC, & Schold SC Jr, : Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:5557, 1992

    • Search Google Scholar
    • Export Citation
  • 10

    Giese A, , Bjerkvig R, , Berens ME, & Westphal M: Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:16241636, 2003

    • Search Google Scholar
    • Export Citation
  • 11

    Herbst RS, , Hess KR, , Tran HT, , Tseng JE, , Mullani NA, & Charnsangavej C, : Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:37923803, 2002

    • Search Google Scholar
    • Export Citation
  • 12

    Inoue S, , Hartman A, , Branch CD, , Bucana CD, , Bekele BN, & Stephens LC, : mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther 15:287294, 2007

    • Search Google Scholar
    • Export Citation
  • 13

    Jain RK, , di Tomaso E, , Duda DG, , Loeffler JS, , Sorensen AG, & Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610622, 2007

    • Search Google Scholar
    • Export Citation
  • 14

    Jain RK, , Tong RT, & Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:27292735, 2007

    • Search Google Scholar
    • Export Citation
  • 15

    Jung YD, , Mansfield PF, , Akagi M, , Takeda A, , Liu W, & Bucana CD, : Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:11331140, 2002

    • Search Google Scholar
    • Export Citation
  • 16

    Kisker O, , Becker CM, , Prox D, , Fannon M, , D'Amato R, & Flynn E, : Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61:76697674, 2001

    • Search Google Scholar
    • Export Citation
  • 17

    Kulke MH, , Bergsland EK, , Ryan DP, , Enzinger PC, , Lynch TJ, & Zhu AX, : Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:35553561, 2006

    • Search Google Scholar
    • Export Citation
  • 18

    Kunwar S, , Chang S, , Westphal M, , Vogelbaum M, , Sampson J, & Barnett G, : Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-oncol 12:871881, 2010

    • Search Google Scholar
    • Export Citation
  • 19

    Lee TY, , Tjin Tham Sjin RM, , Movahedi S, , Ahmed B, , Pravda EA, & Lo KM, : Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 14:14871493, 2008

    • Search Google Scholar
    • Export Citation
  • 20

    Ma J, , Li S, , Reed K, , Guo P, & Gallo JM: Pharmacodynamicmediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 305:833839, 2003

    • Search Google Scholar
    • Export Citation
  • 21

    McGirt MJ, , Than KD, , Weingart JD, , Chaichana KL, , Attenello FJ, & Olivi A, : Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. Clinical article. J Neurosurg 110:583588, 2009

    • Search Google Scholar
    • Export Citation
  • 22

    O'Reilly MS, , Boehm T, , Shing Y, , Fukai N, , Vasios G, & Lane WS, : Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277285, 1997

    • Search Google Scholar
    • Export Citation
  • 23

    Palanichamy K, , Erkkinen M, & Chakravarti A: Predictive and prognostic markers in human glioblastomas. Curr Treat Options Oncol 7:490504, 2006

    • Search Google Scholar
    • Export Citation
  • 24

    Pradilla G, , Legnani FG, , Petrangolini G, , Francescato P, , Chillemi F, & Tyler BM, : Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery 57:10321040, 2005

    • Search Google Scholar
    • Export Citation
  • 25

    Sim BK, , Fogler WE, , Zhou XH, , Liang H, , Madsen JW, & Luu K, : Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3:4151, 1999

    • Search Google Scholar
    • Export Citation
  • 26

    Thomas JP, , Arzoomanian RZ, , Alberti D, , Marnocha R, , Lee F, & Friedl A, : Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223231, 2003

    • Search Google Scholar
    • Export Citation
  • 27

    Tjin Tham Sjin RM, , Naspinski J, , Birsner AE, , Li C, , Chan R, & Lo KM, : Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13:619627, 2006

    • Search Google Scholar
    • Export Citation
  • 28

    Tjin Tham Sjin RM, , Satchi-Fainaro R, , Birsner AE, , Ramanujam VM, , Folkman J, & Javaherian K: A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65:36563663, 2005

    • Search Google Scholar
    • Export Citation
  • 29

    Westphal M, , Hilt DC, , Bortey E, , Delavault P, , Olivares R, & Warnke PC, : A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5:7988, 2003

    • Search Google Scholar
    • Export Citation

Metrics